Skip to main navigation Skip to search Skip to main content

Par-4 prevents breast cancer recurrence

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Therapy resistance and disease recurrence are two of the most challenging aspects in breast cancer treatment. A recent article in Cancer Cell makes a significant contribution toward a better understanding of this therapeutic problem by establishing downregulation of the tumor suppressor Par-4 as the primary determinant of breast cancer recurrence. This viewpoint brings forth the importance of their findings and its implications on future research and therapy.

Original languageEnglish
Article number314
JournalBreast Cancer Research
Volume15
Issue number5
DOIs
StatePublished - Oct 25 2013

Bibliographical note

Funding Information:
This work was supported by National Cancer Institute/National Institutes of Health grant CA060872 and Kentucky Lung Cancer Research grant (to VMR).

Funding

This work was supported by National Cancer Institute/National Institutes of Health grant CA060872 and Kentucky Lung Cancer Research grant (to VMR).

FundersFunder number
Kentucky Lung Cancer Research Association
National Institutes of Health (NIH)
National Childhood Cancer Registry – National Cancer InstituteR01CA060872

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Par-4 prevents breast cancer recurrence'. Together they form a unique fingerprint.

    Cite this